Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 175

1.

Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque.

Walker LM, Sok D, Nishimura Y, Donau O, Sadjadpour R, Gautam R, Shingai M, Pejchal R, Ramos A, Simek MD, Geng Y, Wilson IA, Poignard P, Martin MA, Burton DR.

Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20125-9. doi: 10.1073/pnas.1117531108. Epub 2011 Nov 28.

2.
3.

Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.

Someya K, Cecilia D, Ami Y, Nakasone T, Matsuo K, Burda S, Yamamoto H, Yoshino N, Kaizu M, Ando S, Okuda K, Zolla-Pazner S, Yamazaki S, Yamamoto N, Honda M.

J Virol. 2005 Feb;79(3):1452-62.

4.

Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys.

Amos JD, Himes JE, Armand L, Gurley TC, Martinez DR, Colvin L, Beck K, Overman RG, Liao HX, Moody MA, Permar SR.

J Virol. 2015 Sep;89(18):9485-98. doi: 10.1128/JVI.01564-15. Epub 2015 Jul 8.

5.

Emergence of gp120 V3 variants confers neutralization resistance in an R5 simian-human immunodeficiency virus-infected macaque elite neutralizer that targets the N332 glycan of the human immunodeficiency virus type 1 envelope glycoprotein.

Sadjadpour R, Donau OK, Shingai M, Buckler-White A, Kao S, Strebel K, Nishimura Y, Martin MA.

J Virol. 2013 Aug;87(15):8798-804. doi: 10.1128/JVI.00878-13. Epub 2013 May 29.

6.

Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.

Zolla-Pazner S, Powell R, Yahyaei S, Williams C, Jiang X, Li W, Lu S, Wang S, Upadhyay C, Hioe CE, Totrov M, Kong X.

J Virol. 2016 Nov 28;90(24):10993-11006. Print 2016 Dec 15.

7.
9.

Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.

Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR.

PLoS Pathog. 2009 May;5(5):e1000433. doi: 10.1371/journal.ppat.1000433. Epub 2009 May 15.

10.

Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.

Clements JE, Montelaro RC, Zink MC, Amedee AM, Miller S, Trichel AM, Jagerski B, Hauer D, Martin LN, Bohm RP, et al.

J Virol. 1995 May;69(5):2737-44.

11.

Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model.

Page M, Stebbings R, Berry N, Hull R, Ferguson D, Davis L, Duffy L, Elsley W, Hall J, Ham C, Hassall M, Li B, Mee ET, Quartey-Papafio R, Rose NJ, Mathy N, Voss G, Stott EJ, Almond N.

Retrovirology. 2012 Jul 16;9:56. doi: 10.1186/1742-4690-9-56.

12.

A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals.

Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, Zwick MB, Phogat SK, Poignard P, Burton DR.

PLoS Pathog. 2010 Aug 5;6(8):e1001028. doi: 10.1371/journal.ppat.1001028.

13.

Post-infection immunodeficiency virus control by neutralizing antibodies.

Yamamoto H, Kawada M, Takeda A, Igarashi H, Matano T.

PLoS One. 2007 Jun 20;2(6):e540.

14.

Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.

Yeh WW, Rahman I, Hraber P, Coffey RT, Nevidomskyte D, Giri A, Asmal M, Miljkovic S, Daniels M, Whitney JB, Keele BF, Hahn BH, Korber BT, Shaw GM, Seaman MS, Letvin NL.

J Virol. 2010 Jun;84(12):6018-32. doi: 10.1128/JVI.02741-09. Epub 2010 Mar 31.

15.

Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject.

Mikell I, Stamatatos L.

PLoS One. 2012;7(11):e49610. doi: 10.1371/journal.pone.0049610. Epub 2012 Nov 13.

16.
17.

Epitope specificity of cross-clade neutralizing sera from Chinese HIV-1-positive individuals.

Song H, Chu Y, Zhang H, Wang X, Zhang T, Qiu M, Wu H, Wu Z.

Scand J Immunol. 2013 Oct;78(4):357-70. doi: 10.1111/sji.12091.

18.

Cooperation between Strain-Specific and Broadly Neutralizing Responses Limited Viral Escape and Prolonged the Exposure of the Broadly Neutralizing Epitope.

Anthony C, York T, Bekker V, Matten D, Selhorst P, Ferreria RC, Garrett NJ, Karim SSA, Morris L, Wood NT, Moore PL, Williamson C.

J Virol. 2017 Aug 24;91(18). pii: e00828-17. doi: 10.1128/JVI.00828-17. Print 2017 Sep 15.

19.

Pathogenic infection of Macaca nemestrina with a CCR5-tropic subtype-C simian-human immunodeficiency virus.

Ho O, Larsen K, Polacino P, Li Y, Anderson D, Song R, Ruprecht RM, Hu SL.

Retrovirology. 2009 Jul 14;6:65. doi: 10.1186/1742-4690-6-65.

20.

High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection.

Lavine CL, Lao S, Montefiori DC, Haynes BF, Sodroski JG, Yang X; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).

J Virol. 2012 Feb;86(4):2153-64. doi: 10.1128/JVI.06201-11. Epub 2011 Dec 7.

Supplemental Content

Support Center